title: [Anti HCV drugs--ribavirin, telaprevir].
abstract: The goal of treatment of chronic hepatitis C is the elimination of HCV. Ribavirin and telaprevir are currently used with interferon. In patients with genotype 2 HCV, PEG-IFN+ RBV combination therapy is very effective, but in patients with genotype 1, only SVR can be achieved in only approximately 50%. Furthermore in genotype 1, viral factors i.e. ISDR, IRRDR and/or core amino acid mutations and host factors i.e. IL28B are reported as SVR-related factors. Although the triple therapy with telaprevir resulted in more adverse event it is able to achieve higher SVR by carefully monitoring adverse event and predict to therapeutic effect by previous therapy.
authors.affiliation: Center for Liver Disease, University Hospital, University of Yamanashi.
authors.forename: Minoru
authors.initials: M
authors.lastname: Sakamoto
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Enomoto
mesh_terms: D000998:Antiviral Agents / Q000008:administration & dosage* / Q000494:pharmacology; D004359:Drug Therapy, Combination; D016174:Hepacivirus / Q000187:drug effects*; D006526:Hepatitis C / Q000188:drug therapy*; D006801:Humans; D007372:Interferons / Q000008:administration & dosage* / Q000494:pharmacology; D009842:Oligopeptides / Q000008:administration & dosage* / Q000494:pharmacology; D012254:Ribavirin / Q000008:administration & dosage* / Q000494:pharmacology
chemical_list: D000998:Antiviral Agents; D009842:Oligopeptides; D012254:Ribavirin; C486464:telaprevir; D007372:Interferons